{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T20:27:53Z","timestamp":1783974473671,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T00:00:00Z","timestamp":1547164800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1038\/s41440-018-0201-7","type":"journal-article","created":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T03:26:51Z","timestamp":1547177211000},"page":"514-521","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Mineralocorticoid receptor blockade suppresses dietary salt-induced ACEI\/ARB-resistant albuminuria in non-diabetic hypertension: a sub-analysis of evaluate study"],"prefix":"10.1038","volume":"42","author":[{"given":"Mitsuhiro","family":"Nishimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ohtsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Marumo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wakako","family":"Kawarazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Ayuzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daigoro","family":"Hirohama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiko","family":"Kawakami-Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Nagase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Isshiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyoshi","family":"Oba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Shimosawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,11]]},"reference":[{"key":"201_CR1","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","volume":"31","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, Red\u00f3n J, Zanchetti A, B\u00f6hm M. et al. Task Force Members. 2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281\u2013357.","journal-title":"J Hypertens"},{"key":"201_CR2","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507\u201320.","journal-title":"JAMA"},{"key":"201_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/hr.2013.80","volume":"37","author":"K Shimamoto","year":"2014","unstructured":"Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, et al. Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res. 2014;37:253\u2013390.","journal-title":"Hypertens Res"},{"key":"201_CR4","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","volume":"65","author":"D Zeeuw de","year":"2004","unstructured":"de Zeeuw D, Remuzzi G, Parving H-H, Keane WF, Zhang Z, Shahinfar S, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65:2309\u201320.","journal-title":"Kidney Int"},{"key":"201_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","volume":"41","author":"A Sato","year":"2003","unstructured":"Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003;41:64\u201368.","journal-title":"Hypertension"},{"key":"201_CR6","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2215\/CJN.00240106","volume":"1","author":"M Epstein","year":"2006","unstructured":"Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2006;1:940\u201351.","journal-title":"Clin J Am Soc Nephrol"},{"key":"201_CR7","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1681\/ASN.2009070737","volume":"20","author":"UF Mehdi","year":"2009","unstructured":"Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009;20:2641\u201350.","journal-title":"J Am Soc Nephrol"},{"key":"201_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ejim.2013.11.007","volume":"25","author":"TA Mavrakanas","year":"2014","unstructured":"Mavrakanas TA, Gariani K, Martin P-Y. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review. Eur J Intern Med. 2014;25:173\u20136.","journal-title":"Eur J Intern Med"},{"key":"201_CR9","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H. et al. Mineralocorticoid Receptor Antagonist Tolerability Study\u2013Diabetic Nephropathy (ARTS-DN) Study Group. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314:884\u201394.","journal-title":"JAMA"},{"key":"201_CR10","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S2213-8587(14)70194-9","volume":"2","author":"K Ando","year":"2014","unstructured":"Ando K, Ohtsu H, Uchida S, Kaname S, Arakawa Y, Fujita T. et al. for the EVALUATE Study Group. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:944\u201353.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"201_CR11","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1681\/ASN.2011040430","volume":"23","author":"S Vegter","year":"2012","unstructured":"Vegter S, Perna A, Postma MJ, Navis G, Remuzzi G, Ruggenenti P. Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol. 2012;23:165\u201373.","journal-title":"J Am Soc Nephrol"},{"key":"201_CR12","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1007\/s00125-014-3367-9","volume":"57","author":"L Engelen","year":"2014","unstructured":"Engelen L, Soedamah-Muthu SS, Geleijnse JM, Toeller M, Chaturvedi N, Fuller JH, et al. Higher dietary salt intake is associated with microalbuminuria, but not with retinopathy in individuals with type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetologia. 2014;57:2315\u201323.","journal-title":"Diabetologia"},{"key":"201_CR13","doi-asserted-by":"publisher","first-page":"e109073","DOI":"10.1371\/journal.pone.0109073","volume":"9","author":"SY Han","year":"2014","unstructured":"Han SY, Hong JW, Noh JH, Kim D-J. Association of the estimated 24-h urinary sodium excretion with albuminuria in adult koreans: the 2011 Korea National Health and Nutrition Examination Survey. PLoS ONE. 2014;9:e109073.","journal-title":"PLoS ONE"},{"key":"201_CR14","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1681\/ASN.2013030285","volume":"24","author":"EJ McMahon","year":"2013","unstructured":"McMahon EJ, Bauer JD, Hawley CM, Isbel NM, Stowasser M, Johnson DW, et al. A randomized trial of dietary sodium restriction in CKD. J Am Soc Nephrol. 2013;24:2096\u2013103.","journal-title":"J Am Soc Nephrol"},{"key":"201_CR15","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/ki.1989.190","volume":"36","author":"JE Heeg","year":"1989","unstructured":"Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int. 1989;36:272\u20139.","journal-title":"Kidney Int"},{"key":"201_CR16","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ki.2012.74","volume":"82","author":"HJ Lambers Heerspink","year":"2012","unstructured":"Lambers Heerspink HJ, Holtkamp FA, Parving H-H, Navis GJ, Lewis JB, Ritz E, et al. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int. 2012;82:330\u20137.","journal-title":"Kidney Int"},{"key":"201_CR17","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1172\/JCI43124","volume":"121","author":"S Shibata","year":"2011","unstructured":"Shibata S, Mu S, Kawarazaki H, Muraoka K, Ishizawa K-I, Yoshida S, et al. Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Invest. 2011;121:3233\u201343.","journal-title":"J Clin Invest"},{"key":"201_CR18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/hr.2016.137","volume":"40","author":"S Shibata","year":"2017","unstructured":"Shibata S, Ishizawa K, Uchida S. Mineralocorticoid receptor as a therapeutic target in chronic kidney disease and hypertension. Hypertens Res. 2017;40:221\u20135.","journal-title":"Hypertens Res"},{"key":"201_CR19","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K. et al. Collaborators developing the Japanese equation for estimated GFR.Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"201_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/sj.jhh.1001307","volume":"16","author":"T Tanaka","year":"2002","unstructured":"Tanaka T, Okamura T, Miura K, Kadowaki T, Ueshima H, Nakagawa H, et al. A simple method to estimate populational 24-h urinary sodium and potassium excretion using a casual urine specimen. J Hum Hypertens. 2002;16:97\u2013103.","journal-title":"J Hum Hypertens"},{"key":"201_CR21","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/nm.1879","volume":"14","author":"S Shibata","year":"2008","unstructured":"Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H, et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med. 2008;14:1370\u20136.","journal-title":"Nat Med"},{"key":"201_CR22","doi-asserted-by":"publisher","first-page":"F377","DOI":"10.1152\/ajprenal.00477.2013","volume":"308","author":"M Nishimoto","year":"2015","unstructured":"Nishimoto M, Fujita T. Renal mechanisms of salt-sensitive hypertension: contribution of two steroid receptor-associated pathways. Am J Phsiol Renal Physiol. 2015;308:F377\u201387.","journal-title":"Am J Phsiol Renal Physiol"},{"key":"201_CR23","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1161\/HYPERTENSIONAHA.114.04656","volume":"65","author":"J Fotheringham","year":"2015","unstructured":"Fotheringham J, Odudu A, McKane W, Ellam T. Modification of the relationship between blood pressure and renal albumin permeability by impaired excretory function and diabetes. Hypertension. 2015;65:510\u20136.","journal-title":"Hypertension"},{"key":"201_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","volume":"131","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131:34\u201342.","journal-title":"Circulation"},{"key":"201_CR25","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/hr.2010.46","volume":"33","author":"K Ando","year":"2010","unstructured":"Ando K, Ohtsu H, Arakawa Y, Kubota K, Yamaguchi T, Nagase M. et al. Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect Study Investigators. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. Hypertens Res. 2010;33:616\u201321.","journal-title":"Hypertens Res"},{"key":"201_CR26","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1007\/s10157-009-0177-3","volume":"13","author":"K Suzuki","year":"2009","unstructured":"Suzuki K, Konta T, Takasaki S, Ikeda A, Ichikawa K, Sato H, et al. High variability of albuminuria in nondiabetic population: the Takahata Study. Clin Exp Nephrol. 2009;13:452\u20139.","journal-title":"Clin Exp Nephrol"},{"key":"201_CR27","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.2215\/CJN.01310214","volume":"9","author":"JH Hwang","year":"2014","unstructured":"Hwang JH, Chin HJ, Kim S, Kim DK, Kim S, Kim S, et al. Effects of intensive low-salt diet education on albuminuria among nondiabetic patients with hypertension treated with olmesartan: a single-blinded randomized, controlled trial. Clin J Am Soc Nephrol. 2014;9:2059\u201369.","journal-title":"Clin J Am Soc Nephrol"},{"key":"201_CR28","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.2215\/CJN.00550113","volume":"8","author":"RM Tanner","year":"2013","unstructured":"Tanner RM, Calhoun DA, Bell EK, Bowling CB, Guti\u00e9rrez OM, Irvin MR, et al. Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol. 2013;8:1583\u201390.","journal-title":"Clin J Am Soc Nephrol"},{"key":"201_CR29","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.169961","volume":"57","author":"J V\u00e1clav\u00edk","year":"2011","unstructured":"V\u00e1clav\u00edk J, Sedl\u00e1k R, Plachy M, Navr\u00e1til K, Pl\u00e1sek J, Jarkovsky J, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57:1069\u201375.","journal-title":"Hypertension"},{"key":"201_CR30","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1161\/HYPERTENSIONAHA.109.131235","volume":"54","author":"E Pimenta","year":"2009","unstructured":"Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell\u2019Italia LJ, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009;54:475\u201381.","journal-title":"Hypertension"},{"key":"201_CR31","doi-asserted-by":"publisher","first-page":"e003733","DOI":"10.1136\/bmjopen-2013-003733","volume":"3","author":"J Powles","year":"2013","unstructured":"Powles J, Fahimi S, Micha R, Khatibzadeh S, Shi P, Ezzati M. et al.Global Burden of Diseases Nutrition and Chronic Diseases Expert Group (NutriCoDE) Global, regional and national sodium intakes in 1990 and 2010: a systematic analysis of 24 h urinary sodium excretion and dietary surveys worldwide. BMJ Open. 2013;3:e003733\u2013e003733.","journal-title":"BMJ Open"},{"key":"201_CR32","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1017\/S0007114514001779","volume":"112","author":"K Asakura","year":"2014","unstructured":"Asakura K, Uechi K, Sasaki Y, Masayasu S, Sasaki S. Estimation of sodium and potassium intakes assessed by two 24 h urine collections in healthy Japanese adults: a nationwide study. Br J Nutr. 2014;112:1195\u2013205.","journal-title":"Br J Nutr"},{"key":"201_CR33","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1056\/NEJMoa1311889","volume":"371","author":"M O\u2019Donnell","year":"2014","unstructured":"O\u2019Donnell M, Mente A, Rangarajan S, McQueen MJ, Wang X, Liu L. et al. PURE Investigators. Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med. 2014;371:612\u201323.","journal-title":"N Engl J Med"},{"key":"201_CR34","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1093\/ajh\/hpt139","volume":"26","author":"DA McCarron","year":"2013","unstructured":"McCarron DA, Kazaks AG, Geerling JC, Stern JS, Graudal NA. Normal range of human dietary sodium intake: a perspective based on 24-hour urinary sodium excretion worldwide. Am J Hypertens. 2013;26:1218\u201323.","journal-title":"Am J Hypertens"},{"key":"201_CR35","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1161\/HYPERTENSIONAHA.115.05948","volume":"66","author":"Y Ma","year":"2015","unstructured":"Ma Y, He FJ, Macgregor GA. High salt intake: independent risk factor for obesity? Hypertension. 2015;66:843\u20139. \n                    https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.115.05948","journal-title":"Hypertension"},{"key":"201_CR36","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1373\/clinchem.2004.033159","volume":"50","author":"FH Perschel","year":"2004","unstructured":"Perschel FH, Schemer R, Seiler L, Reincke M, Deinum J, Maser-Gluth C, et al. Rapid screening test for primary hyperaldosteronism: ratio of plasma aldosterone to renin concentration determined by fully automated chemiluminescence immunoassays. Clin Chem. 2004;50:1650\u20135.","journal-title":"Clin Chem"},{"key":"201_CR37","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/hr.2009.86","volume":"32","author":"M Nagase","year":"2009","unstructured":"Nagase M, Fujita T. Mineralocorticoid receptor activation in obesity hypertension. Hypertens Res. 2009;32:649\u201357.","journal-title":"Hypertens Res"},{"key":"201_CR38","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1210\/jc.2010-0225","volume":"95","author":"AH Ahmed","year":"2010","unstructured":"Ahmed AH, Gordon RD, Taylor P, Ward G, Pimenta E, Stowasser M, et al. Effect of atenolol on aldosterone\/renin ratio calculated by both plasma renin activity and direct renin concentration in healthy male volunteers. J Clin Endocrinol Metab. 2010;95:3201\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"201_CR39","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1177\/1753944712452191","volume":"6","author":"H Suzuki","year":"2012","unstructured":"Suzuki H, Shuto H, Shuto C, Ohara I, Inokuma S, Abe Y, et al. Eplerenone, an aldosterone blocker, is more effective in reducing blood pressure in patients with, than without, metabolic syndrome. Ther Adv Cardiovasc Dis. 2012;6:141\u20137.","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"201_CR40","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1291\/hypres.30.887","volume":"30","author":"Y Kawano","year":"2007","unstructured":"Kawano Y, Tsuchihashi T, Matsuura H, Ando K, Fujita T, Ueshima H. et al.Working Group for Dietary Salt Reduction of the Japanese Society of Hypertension. Report of the Working Group for Dietary Salt Reduction of the Japanese Society of Hypertension: (2) Assessment of salt intake in the management of hypertension. Hypertens Res. 2007;30:887\u201393.","journal-title":"Hypertens Res"},{"key":"201_CR41","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1681\/ASN.2014070688","volume":"26","author":"HJ Lambers Heerspink","year":"2014","unstructured":"Lambers Heerspink HJ, Kr\u00f6pelin TF, Hoekman J, de Zeeuw D, on behalf of the, Reducing Albuminuria as Surrogate Endpoint (REASSURE) Consortium. Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis. J Am Soc Nephrol. 2014;26:2055\u201364.","journal-title":"J Am Soc Nephrol"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41440-018-0201-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41440-018-0201-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41440-018-0201-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:20:15Z","timestamp":1684617615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-018-0201-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,11]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["201"],"URL":"https:\/\/doi.org\/10.1038\/s41440-018-0201-7","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,11]]},"assertion":[{"value":"22 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors indicated no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}